InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,419.20
(
0.00%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.46
(
0.40%
)
Bitcoin
64,254.94
(
0.42%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 206603

Tuesday, 12/06/2016 9:01:11 AM

Tuesday, December 06, 2016 9:01:11 AM

Post# of 251721
Update on SAGE’s phase-3 program in PPD:

http://finance.yahoo.com/news/sage-announces-expedited-development-plan-120000253.html

The current SAGE-547 program in PPD, along with prior Phase 2 data, were confirmed as supporting, if successful, a potential New Drug Application (NDA). Sage’s PPD clinical program, now in Phase 3, will require only minor modifications, including an increase in sample size. Agreement with the FDA was achieved on the clinical endpoints for these pivotal trials. Sage anticipates announcing top-line data from the PPD registration trials in 2H 2017.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up